SETDB1 is a histone H3K9 methyltransferase that plays critical roles in genome stability, immune regulation, and disease pathogenesis. Functionally, SETDB1 catalyzes H3K9 mono-, di-, and trimethylation to establish heterochromatin and silence repetitive elements, particularly endogenous retroviruses 12. The enzyme works with cofactors like TRIM28 to form repressive complexes that maintain chr1 stability 3. SETDB1 suppresses tumor-intrinsic immunogenicity by silencing transposable elements and immune-stimulatory genes, with its amplification associated with immune exclusion and checkpoint blockade resistance 1. Loss of SETDB1 derepresses endogenous retroviruses, activating cytosolic RNA/DNA sensing pathways and triggering innate immune responses including cGAS-STING signaling 34. Beyond chr1 regulation, SETDB1 exhibits non-histone methyltransferase activity, directly methylating proteins like MCT1 to regulate lactate metabolism and tumor progression 5. Clinically, SETDB1 deficiency contributes to inflammatory bowel disease pathogenesis through genome instability and stem cell necroptosis 2, while its dysregulation is implicated in alcoholic liver disease 6 and cancer progression 78. These diverse functions establish SETDB1 as a critical epigenetic regulator with significant therapeutic potential across multiple disease contexts.